The increased risk of several types of cancer in Klinefelter syndrome (47XXY) suggests that the extra X chromosome may be involved in the tumorigenesis associated with this syndrome. Here, we show that cancer cells (PSK-1) derived from a patient with Klinefelter syndrome (47XXY) showing loss of an inactive X chromosome subsequently gained active X chromosomes. We found that this abnormal X chromosome composition in PSK-1 is caused by a loss of an inactive X chromosome followed by multiplication of identical active X chromosomes, not by reactivation of an inactive X chromosome. Furthermore, we extended the characterization of loss-of-inactive X in a series of 22 female-derived cancer cell lines (eight breast cancer cell lines, seven ovarian cancer cell lines, and seven cervical cancer cell lines). The data demonstrate that lossof-inactive X in the female-derived cancer cells is mainly achieved by loss of an inactive X chromosomes followed by multiplication of an identical active X chromosomes. However, distinctive pathways, including reactivation of an inactive X chromosome, are also involved in the mechanisms for loss-of-inactive X and gain-of-active X in female-derived cancer cells. The biological significance of the loss-of-inactive X and gain-of-active X in the oncogenesis of Klinefelter syndrome and female-derived cancer cells are discussed.
Klinefelter syndrome is a sex chromosome abnormality with a prevalence of 1/500 in males (Smyth and Bremner, 1998) . Patients with Klinefelter syndrome (47XXY) have an increased risk of developing several types of cancer, such as breast cancer and extragonadal germ-cell tumors (Hasle et al., 1995; Smyth and Bremner, 1998) . In particular, breast cancer occurs only rarely in men, but Klinefelter syndrome confers a 50-fold increased risk compared with the risk in XY men (Giordano et al., 2002) . Although the mechanisms underlying the high susceptibility to cancer in Klinefelter syndrome remain unresolved, it seems possible that the extra X chromosome may play a role in the tumorigenesis of this syndrome. However, due to the lack of an established cancer cell line from patients with Klinefelter syndrome, there has been no evidence to show a direct role of the X chromosomes in the tumorigenesis. Recently, a small-cell carcinoma cell line (PSK-1) originating from a Klinefelter syndrome patient has been established (Kim et al., 2000) . This cell line has allowed us to study and compare X inactivation status in peripheral blood lymphocytes (PBL) and PSK-1. In the present study, we show that PSK-1 cells demonstrate a loss of an inactive X chromosome and multiplication of active X chromosomes, while the patient's PBLs carry the normal female complement of two different (active and inactive) X chromosomes (47XXY). Furthermore, we extended the characterization of loss-of-inactive X to a series of female-derived cancer cell lines (breast, ovary, and cervical cancers). The mechanisms and biological significance underlying the loss-of-inactive X in the Klinefelter syndrome cancer and female-derived cancer cells are discussed.
We first analysed XIST expression in PSK-1, a smallcell carcinoma cell line of the prostate-derived from a patient with Klinefelter syndrome, and the matched PBLs (47XXY). Samples from the Klinefelter syndrome patient were obtained with fully informed consent. We found XIST expression in PBLs of the Klinefelter syndrome patient that was similar to that in femalederived PBLs (Figure 1a ). In contrast, we observed that XIST expression was lost in PSK-1 (Figure 1a ). To explore further the mechanism behind the loss of XIST expression in PSK-1, we conducted a numerical analysis of X chromosomes in PSK-1. We used FISH to determine the number of X chromosomes per nucleus in PSK-1 and matched PBLs (Figure 1b) . PSK-1 Figure 1 Loss-of-X inactivation and gain-of-X activation in cancer cells (PSK-1) derived from a patient with Klinefelter syndrome. The PBLs were isolated using lymphocyte separation medium, and were then used after stimulation with phytohemagglutinin-M (PHA-M) (Boehringer Mannheim GmbH, Mannheim, Germany) in RPMI 1640 medium with 10% FBS. 0 -AGG CAC CAG GGC GTG ATG GT-3 0 and (antisense) 5 0 -GGT CTC AAA CAT GAT CTG GG-3 0 , were also used to monitor b-actin as control for RT-PCR. M, molecular weight marker. PBL male, male-derived PBLs; PBL female, female-derived PBLs; PBL 47XXY, PBLs from a Klinefelter syndrome patient; PSK-1, a small-cell carcinoma of the prostate cell line derived from a patient with Klinefelter syndrome. (b) Numerical analysis of X chromosome in PSK-1 and matched PBLs (47XXY). FISH studies of PSK-1 and matched PBLs (47XXY) are shown. The number of X chromosomes was determined by FISH using the X-chromosomespecific probe, CEP X (VYSIS, Framingham, MA, USA), which hybridizes to repetitive sequences located near the X chromosome centromere (Kawakami et al., 2003b) . The evaluation and counting of FISH signals were conducted according to the criteria of Hopman et al. (1989) . The number of X chromosomes was determined from the most frequent modal copy numbers. Note that PSK-1 carries three X chromosomes while the matched PBLs (47XXY) carries two X chromosomes similar to female-derived PBLs. (c) The analysis of CpG methylation status of the FMR-1 promoter in PSK-1 and matched PBL (47XXY). (Top) CpG plots across FMR 1 are shown. The arrows show the start of transcription. The black bars indicate the start of the coding regions. CpG sites across the FMR1 are indicated by a vertical tick. The CpG sites analysed by bisulfite genomic sequencing are magnified and numbered on top of the ticks. (Bottom) Chromatographs of direct bisulfite genomic sequencing of FMR1 are shown. Male PBLs demonstrate completely unmethylated peaks, while female PBLs demonstrate a nearly equal ratio of methylated and unmethylated peaks suggesting the primer pairs used to amplify methylated and unmethylated DNA without major bias. The numbered arrows in the female PBL chromatographs correspond to the CpG plots on top. Each arrow in the chromatograph demonstrates the presence of methylated alleles. Note the chromatographs of PSK-1 showing the absence of methylated alleles, while the matched PBLs (47XXY) show an equal ratio of methylated and unmethylated peaks. Bisulfite genomic sequencing of the FMR-1 promoter was conducted according to the following methods: genomic DNA preparation and bisulfite treatment were performed as described previously (Kawakami et al., 2003a) . The primer pairs used for bisulfite genomic sequencing are: Outer 1, 5 0 -GGA ATT TTA GAG AGG TCG AAT TGG G (forward, modified from nt 2246 to 2270 by Accession No. X62378); Outer 2, 5 0 -CCC TCT CTC TTC AAA TAA CCT AAA AAC (reverse, modified from nt 2492 to 2466); Inner 1, 5 0 -GTT ATT GAG TGT ATT TTT GTA GAA ATG GG (forward, modified from nt 2296 to 2325); Inner 2, 5 0 -CCC TCT CTC TTC AAA TAA CCT AAA AAC (forward, modified from nt 2492 to 2466) (Kawakami et al., 2003b) . The PCRs were performed on a Peltier Thermal Cycler-200 (MJ Research, Watertown, MA, USA) using previously described PCR cycling programs (Melki et al., 1999) with annealing temperatures of 501C for the first round of PCR and 551C for the second round of PCR. The purified fragments were sequenced according to methods described previously (Kawakami et al., 2003b) . (d) Representative X chromosomal microsatellite analysis of PSK-1 and matched PBLs (47XXY). Chromatographs using DXS 6803, DXS9898, and DXS6789 are shown. (Top) Chromatographs of DNA from the matched PBLs (47XXY). (Bottom) Chromatographs of DNA from PSK-1. Note that PSK-1 shows homozygosity while the matched PBLs (47XXY) shows heterozygosity at DXS 6803, DXS9898, and DXS6789. The allelic status of the X chromosome was studied using seven highly polymorphic markers (DXS9895, DXS9898, DXS7132, DXS101, DXS6803, DXS5789, and DXS7424). PCR products were separated electrophoretically on a 5% polyacrylamide gel and detected by laser fluorescence using an automated sequencer (ALF, Pharmacia, Biotech). Fluorescence gel data were collected automatically during electrophoresis using the Fragment Manager (FM 1.1) software (Pharmacia, Biotech). The allelic status in PSK-1 was examined by comparing the allelic status of the matched PBL DNA Loss-of-inactive X and gain-of-active X in cancer T Kawakami et al contained three X chromosomes while the matched PBLs (47XXY) contained two. The number of X chromosomes in PSK-1 was in accordance with the previous karyotyping data with a mode of 82 chromosomes (Kim et al., 2000) . In order to determine the X inactivation status of the supernumerical X chromosomes in PSK-1, we evaluated the methylation status of the X chromosomes in the patient's PBLs and PSK-1; we conducted bisulfite genomic sequencing of fragile X mental retardation (FMR1), which is inactivated via promoter methylation in inactivated X chromosomes (Kirchgessner et al., 1995) . We selected FMR-1 among other X-linked genes because FMR-1 appears to be a gene that is unrelated to oncogenesis and strictly subject to X inactivation (Brown et al., 1997; McDonald et al., 2000) . Furthermore, our laboratory data and those of others have shown that FMR-1 is less likely to be affected by aberrant methylation in cancer cells than are other Xlinked gene (McDonald et al., 2000; Kawakami et al., 2003b) . We therefore selected FMR-1 as a reliable marker of X inactivation in cancer cells as well as the normal cell population. The CpG plots across the FMR1 gene, the CpG sites analysed by bisulfite genomic sequencing, and the results of the bisulfite sequencing is shown in Figure 1c . PSK-1 showed no detectable levels of methylated alleles on FMR-1, while the patient PBLs showed hemimethylation similar to that in female PBLs. Thus, we concluded that the three X chromosomes in PSK-1 are predominantly active X chromosomes, while the patient PBLs (47XXY) carry the normal female complement of two different (active and inactive) X chromosomes.
To further elucidate the underlying mechanisms of the loss of an inactive X chromosome and gain of active X chromosomes in PSK-1, we tested whether the multiple active X chromosomes in PSK-1 are heterozygous or homozygous using different polymorphic X chromosome markers. We conceived two scenarios to explain the loss-of-inactive X and gain-of-active X in PSK-1: (1) if PSK-1 demonstrates retention of heterozygosity at different markers, loss-of-inactive X and gain-of-active X in PSK-1 could be generated by reactivation of an inactive X chromosome; (2) if PSK-1 demonstrates loss of heterozygosity at every marker tested, loss-of-inactive X and gain-of-active X in PSK-1 could be generated by the loss of an inactive X chromosome accompanied by gain of an active X chromosome through chromosomal nondisjunction.
We used seven different polymorphic markers on the X chromosome (% heterozygosity is shown in parentheses): DXS9895 (0.73) (Son et al., 2002) ; DXS7132 (0.69) (Son et al., 2002) ; DXS6803 (0.69) (Huang et al., 2003) ; DXS9898 (0.67) (Son et al., 2002) ; DXS 6789 (0.84) (Son et al., 2002) ; DXS 101 (0.88) (Edelmann and Szibor, 2001 ); DXS 7424 (0.84) (Edelmann et al., 2002) . Representative chromatographs, using DXS6803, DXS9898, and DXS6789 of the patient PBLs and PSK-1 are shown (Figure 1d ). The multiple active X chromosomes in PSK-1 were homozygous at DXS6803, DXS9898, and DXS6789, while the matched PBLs (47XXY) demonstrated heterozygosity at the three markers (Figure 1d ). The loss of heterozygosity in PSK-1 was further identified at three additional markers, DXS7132, DXS101, and DXS7424 (Table 1) . The matched PBLs (47XXY) were not informative at a single marker (DSX9895). Thus, we concluded that the loss-of-inactive X and gain-of-active X in PSK-1 are caused through loss of an inactive X chromosome followed by multiplication of an identical active X chromosome.
In order to see whether the abnormal X chromosome composition observed in PSK-1 is a common feature in female-derived neoplasms, we performed similar studies using additional 22 female-derived cancer cell lines (breast cancer, ovarian cancer, and cervical cancer). A summary of the results is shown in Table 1 . The loss of XIST expression completely matched the absence of methylation at the FMR1 gene promoter while the maintained XIST expression completely matched the presence of methylation at the FMR1 gene: 13 of the 22 cell lines (59%) demonstrated loss of XIST expression and a nondetectable level of methylation at the FMR1 gene, similar to the situation in PSK-1.
Thus, these 13 cell lines were considered as having loss-of-inactive X. Among the 13 cell lines with loss-ofinactive X (cell lines with loss of XIST expression and absence of FMR1 methylation), 11 cell lines (85%) were found to carry multiple active X chromosomes similar to those in PSK-1. In contrast, loss of an active X chromosome, judged by an increased level of methylation at FMR1 in excess of 50%, was not observed in any of the 22 cell lines. This implies that loss of an active X chromosome followed by a predominant gain of inactive X chromosomes are unlikely events. As the methylation assay used in this study is semiquantitative, we could not differentiate the presence of a single inactive X chromosome from that of multiple inactive X chromosomes. Therefore, in the presence of methylation we could not determine the exact X chromosomal composition of cell lines with three or more X chromosomes (see Table 1 legends).
To further evaluate the loss-of-inactive X in femalederived cancer cells, we examined the allelic status of X chromosomes using seven microsatellite markers at different X chromosomal loci. Since normal DNA was not available of the patients from whom our series of female-derived cell lines originated, a comparison study between these cancer cell lines and the matched PBLs could not be performed. Alternatively, the allelic status was inferred by analysis of cell line genotypes at the multiple loci: cell lines with constitutional homozygosity at the seven contiguous markers used in this study suggested the presence of identical X chromosomes because there is a very small probability that these different loci markers would be homozygous by chance (less than 0.00005). The allelic status of X chromosomes in the 22 female-derived cell lines revealed that 11 cell lines (50%) showed constitutional homozygosity at every X chromosomal locus tested, suggesting that the 11 cell lines carry identical X chromosome(s) ( Table 1) . 
The number of X chromosomes was determined from the most frequent modal copy numbers. XIST expression is shown as null (À) or positive (+). Methylation status of FMR-1 was determined by comparing the intensity of sequencing electropherogram of cytosine with that of thymine at each CpG site. The direct sequencing electropherogram allowed us to measure the degree of methylation in a semiquantitative fashion. Under the conditions, the patterns of methylation at FMR-1 in our series of samples were identified as either unmethylation (complete absence of methylated peaks) or hemimethylation (equal ratio of unmethylated and methylated peaks). Therefore we classified the methylation profiles of FMR1 into unmethylation and hemimethylation. Methylation profiling of the CpG island of the FMR1 gene is shown as: Open ovals, unmethylation; white dotted ovals, hemimethylation. The allelic status of X chromosomes is shown as white filled squares, heterozygous; black filled squares, homozygous. X chromosome composition is shown as Xa, an active X chromosome; Xi, an inactive X chromosome; Xu, active or inactive state was undetermined because the methylation assay used in this study is semiquantitative. *gain of active X chromosome by reactivation of an inactive X chromosome. KS, Klinefelter's syndrome; PBL, peripheral blood leukocytes; ND, not determined. Five breast cancer cell lines (YMB-1E, MRK-NU1, CRL1500, MDA-MB-453, and OCUB-F) were purchased from Riken Cell Bank (Tsukuba, Japan). Six ovarian cancer cell lines (RMG-I, RMG-II, RKN, RTSG, RMUG-L, TYK-nu) and three cervical carcinoma cell lines (BOKU, SKG-II, and HeLa) were purchased from Japanese Collection of Research Bioresources. An ovarian cancer cell line OVK18 and four cervical carcinoma cell lines (D98-AH2, CaSki, ME-180, and SKG-IIIa) were purchased from Institute of Development, Aging and Cancer, Tohoku University. Two breast cancer cell lines (T47D, and SK-BR-3) were obtained from Dr Keiichi Kontani at the Shiga University of Medical Science (Shiga, Japan).
Loss-of-inactive X and gain-of-active X in cancer
Through the data, we were able to classify the loss-ofinactive X in female-derived cancer cells into three patterns: (1) loss of an inactive X chromosome without the gain of active X chromosomes (two ovarian cancer cell lines, RMG-I and RMG-II) (two of 13 cell lines, 15%); (2) loss of an inactive X chromosome followed by multiplication of active X chromosomes into identical copies, similar to those in PSK-1 (three of three breast cancer cell lines with loss-of-inactive X, two of six ovarian carcinoma cell lines with loss-of-inactive X, and four of four cervical carcinomas with loss-of-inactive X) (nine of 13 cell lines, 69%); (3) reactivation of an inactive X chromosome (two ovarian cancer cell lines, RTSG and RMUG-L) (two of 13 cell lines, 15%).
In order to confirm reactivation of the X chromosome in the two ovarian cancer cell lines (RTSG and RMUG-L), we conducted two additional experiments.
First, we studied the methylation status of the XIST 5 0 end in these cell lines. We have currently shown that the XIST 5 0 end is differentially methylated in femalederived somatic cells according to the inactive status of two X chromosomes (Kawakami et al., 2004) . The results showed that DNAs of RTSG and RMUG-L carry methylated, but not unmethylated alleles (Figure 2 ). Considering that RTSG and RMUG-L were heterozygous at DXS6803, XIST locus (Xq13), these results support the conclusion that both of the two polymorphic X chromosomes are active.
Second, to see biallelic expression of X-linked gene in these cell lines, we employed allele-specific PCR of the p55 gene. The technique has been described previously (McDonald et al., 2000) . We designed new allele-specific primers for p55 using detection of G and T alleles in exon 3 (Figure 3a) . Of the two cell lines, RTSG was informative at the polymorphic site, while RMUG-L was not informative. Allele-specific reverse transcription-polymerase chain reaction (RT-PCR) revealed that RTSG expressed p55 from two heterozygous X chromosomes (Figure 3b ). The data show convincingly reactivation of an inactive X chromosome in RTSG. So far, reactivation of an inactive X chromosome has been well documented in a case with structural rearrangement: t (X;15)(q23;q25) in a lymphoblastoid cell line from a patient with Fanconi anemia results in segmental reactivation of Xq23-qter while Xpter-q23 remains inactive (Kokalj-Vokac et al., 1991) . Segmental reactivation can occur by separating genes from the XIST or XIC (position effect). In this case, XIST expression should be retained to maintain inactive state of the remained X (Xpter-q23). On the other hand, XIST expression is lost in the two ovarian cancer cell lines with heterozygous X chromosomes (RTSG and RMUG-L). Thus, segmental reactivation of X chromosome by rearrangement occurs unlikely in RTSG and RMUG-L although this must be further clarified by showing polymorphic expression at different genes. We have demonstrated that cancer cells (PSK-1) showing loss of an inactive X chromosome, derived from a patient with Klinefelter syndrome (47XXY), subsequently gained active X chromosomes. We found that this abnormal X chromosome composition in PSK-1 is caused by loss of an inactive X chromosome 0 end was examined by methylation-specific PCR (Kawakami et al., 2004) . We used primer pairs amplifying methylated (M) and unmethylated (U) DNA specifically (Kawakami et al., 2004) . Representative MSP profiles of the female-derived cell lines are shown; an unmethylated signal in PBLs is identified exclusively in female PBLs, while a methylated signal is identified both in male-and female-derived PBLs. Note that RTSG and RMUG-L demonstrate only methylated signals, while OVK18 (a cell line with XaXi complement as shown in Table  1 ) demonstrates both methylated and unmethylated signals Loss-of-inactive X and gain-of-active X in cancer T Kawakami et al followed by multiplication of the remaining active X chromosome into identical copies, not by reactivation of an inactive X chromosome. Furthermore, we have found that this abnormal X chromosome composition is a general phenomenon in several types of femalederived cancer cells (breast, ovarian, and cervical carcinomas) .
Prior evidence demonstrated that a Barr body (a cytogenetically visible inactive X chromosome) is frequently lost in breast, ovarian, and cervical carcinomas and that this is associated with a poor prognosis (Savino, 1971; Perry, 1972; Therman et al., 1985) . Recently, Huang et al. (2002) have studied global RNA expression profiles in primary and recurrent ovarian tumors. They found that XIST is the most differentially expressed gene that is downregulated in recurrent ovarian carcinomas. They also reported that loss of XIST expression was correlated with resistance of ovarian cancer to chemotherapy. However, mechanisms whereby Barr body loss influences oncogenic progression in these tumors remain unresolved. Huang et al. (2002) suggested that loss of an inactive X chromosome may be one mechanism that could account for the loss of XIST expression in some ovarian carcinoma cell lines. Our study has extended these results. We observed that abnormal X chromosome compositions in female-derived cancer cells have several characteristics. First, similar to the situation in PSK-1, multiplication of active X chromosomes was accompanied in most of the female-derived cancer cells with loss of an inactive X chromosome. Furthermore, we show that this process was mainly achieved by chromosomal nondisjunction rather than reactivation of an inactive X chromosome, although this apparently does take place in some cell lines. In contrast, we observed that loss of an active X chromosome is rare in our series of cell lines. The mechanisms underlying these preferential losses of an inactive X chromosome and gain of active X chromosomes remain to be clarified. One possibility is that asynchronous replication timing of two X chromosomes (early replication of an active X chromosome and late replication of an inactive X chromosome) may have some effect on this preferential nondisjunction of X chromosomes. Indeed, an earlier study suggested a tendency to gaining early-replicating X and losing late-replicating X in female cancers (Dutrillaux et al., 1986) . Similarly, a gain of early replicating X chromosomes has been shown in colorectal cancer (Muleris et al., 1990) .
Recent striking findings by Ganesan et al. (2002) show that BRCA1 dysfunction results in failure of X chromosome inactivation: BRCA1 interacts and colocalizes with XIST, and BRCA1 protein is crucial for X inactivation (Stone et al., 2003) . Breast and ovarian carcinoma cells lacking BRCA1 show defects in the inactive X chromatin structure. Inhibition of BRCA1 synthesis in a suitable reporter line led to increased expression of an otherwise silenced Xi-located GFP transgene. The observations by Ganesan et al. (2002) suggest that loss of BRCA1 in female cells may lead to Xi perturbation and destabilization of its silenced state.
The data by Ganesan et al. appear to show reactivation of an inactive X chromosome in BRCA1-deficient breast and ovarian cell lines because restoration of focal XIST staining was observed by reconstituting BRCA1-deficient cells with wild-type BRCA1. Furthermore, the data show that acute suppression of BRCA1 synthesis was associated with a significant loss of focal XIST staining. Although we did not examine BRCA1 mutations in our series of female cell lines, we can state that BRCA1 expression was well maintained in all of the 22 cell lines tested (data not shown). Evaluating the evidence presented in our study together with published data lead us to the following conclusions: gain of active X chromosomes through reactivation of an inactive X chromosome indeed exists in female-derived cancers, but is probably an infrequent event. Rather, loss of an inactive X chromosome followed by multiplication of remaining active X chromosomes into identical active copies is a major pathway for loss of XIST expression in female-derived cancer cells. However, distinctive pathways seem to be involved in the mechanisms for loss-ofinactive X and gain-of-active X in female-derived cancer cells. We cannot generalize tumorigenesis of Klinefelter syndrome from analysing X chromosomal composition in one cell line. Additional numbers of tumor cell lines derived from Klinefelter syndrome individuals must be studied to see whether the present observation contributes to the tumorigenesis of this syndrome.
The biological significance of the abnormal X chromosomal compositions in tumors must be elucidated further. X chromosomes in female somatic cells (XX) are strictly under the control of dosage compensation, known as X chromosome inactivation: one of two X chromosomes in females is silenced in order to achieve transcriptional balance with the XY male (Lyon, 1961) . The dosage compensation also functions well in 47XXY, as shown in our study. This is consistent with the previous report that the extra X chromosome forms a Barr body within the nuclei of somatic cells derived from an individual with Klinefelter syndrome (Jacobs and Strong, 1959) . The loss-of-inactive X followed by gainof-active X found in the present study signifies disruption of the dosage compensation. This phenomenon may imply oncogenic, rather than tumor suppressor, roles of X chromosomes in Klinefelter syndrome and femalederived cancer cells.
It is tempting to speculate that the extra active X chromosomes result in advantages for tumor growth by increasing gene dosages. We have already shown that Xlinked oncogenes, such as ARAF-1 and ELK-1, are overexpressed in testicular germ-cell tumors with multiple active X chromosomes (Kawakami et al., 2003b) . Similarly, we have observed enhanced expression of ARAF-1 and ELK-1 in PSK-1 (unpublished data). Another group has shown that BRCA-1-deficient ovarian cancers exhibit overexpression of a set of X chromosomal genes, including ARAF1 (Jazaeri et al., 2002) . The sum of these data indicate that accumulation of active X chromosomes may result in over-representation of X-linked genes, including oncogenes, which may provide a growth advantage to cancer cells.
Here, we have demonstrated that loss of an inactive X chromosome is frequently associated with multiplication of active X chromosomes in Klinefelter syndrome and female-derived neoplasms. We believe that the loss of an inactive X chromosome and the subsequent accumulated gain of active X chromosomes launch a new exciting area in cancer research. Further study on the cancer cells derived from Klinefelter syndrome patients are warranted.
